Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function

on behalf of the Italian EAP working Group

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We report preliminary data on the six month use of Nusinersen in 104 type 1 patients of age ranging from three months to 19 years, 9 months. Ten of the 104 were classified as 1.1, 58 as 1.5 and 36 as 1.9. Three patients had one SMN2 copy, 65 had two and 24 had three copies. In 12 the SMN2 copy number was not available. After six months an improvement of more than two points was found in 58 of the 104 (55.7%) on the CHOP INTEND and in 21 of the 104 (20.19%) on the Hammersmith Infant Neurological Examination (HINE). Changes more than two points were found in 26/71 patients older than two years, and in seven of the 20 older than 10 years. Changes ≥ four points were found in 20/71 older than two years, and in six of the 20 patients older than 10 years. The difference between baseline and six months on both CHOP INTEND and HINE was significant for the whole group (p < 0.001) as well as for the subgroups with two (p < 0.001), and three SMN2 copies (p < 0.001). Our preliminary results suggest that functional improvement can be observed in type 1 patients outside the range of the inclusion criteria used in the Endear study.

Original languageEnglish
Pages (from-to)582-585
Number of pages4
JournalNeuromuscular Disorders
Volume28
Issue number7
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Young Adult
Neurologic Examination

Keywords

  • CHOP INTEND
  • Hammersmith Infant Neurological Examination
  • Nusinersen
  • Spinal Muscular Atrophy
  • Werdnig Hoffmann disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Clinical Neurology
  • Genetics(clinical)

Cite this

Nusinersen in type 1 SMA infants, children and young adults : Preliminary results on motor function. / on behalf of the Italian EAP working Group.

In: Neuromuscular Disorders, Vol. 28, No. 7, 01.07.2018, p. 582-585.

Research output: Contribution to journalArticle

on behalf of the Italian EAP working Group. / Nusinersen in type 1 SMA infants, children and young adults : Preliminary results on motor function. In: Neuromuscular Disorders. 2018 ; Vol. 28, No. 7. pp. 582-585.
@article{f3de91a4477a484fa1dfb11be5886992,
title = "Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function",
abstract = "We report preliminary data on the six month use of Nusinersen in 104 type 1 patients of age ranging from three months to 19 years, 9 months. Ten of the 104 were classified as 1.1, 58 as 1.5 and 36 as 1.9. Three patients had one SMN2 copy, 65 had two and 24 had three copies. In 12 the SMN2 copy number was not available. After six months an improvement of more than two points was found in 58 of the 104 (55.7{\%}) on the CHOP INTEND and in 21 of the 104 (20.19{\%}) on the Hammersmith Infant Neurological Examination (HINE). Changes more than two points were found in 26/71 patients older than two years, and in seven of the 20 older than 10 years. Changes ≥ four points were found in 20/71 older than two years, and in six of the 20 patients older than 10 years. The difference between baseline and six months on both CHOP INTEND and HINE was significant for the whole group (p < 0.001) as well as for the subgroups with two (p < 0.001), and three SMN2 copies (p < 0.001). Our preliminary results suggest that functional improvement can be observed in type 1 patients outside the range of the inclusion criteria used in the Endear study.",
keywords = "CHOP INTEND, Hammersmith Infant Neurological Examination, Nusinersen, Spinal Muscular Atrophy, Werdnig Hoffmann disease",
author = "{on behalf of the Italian EAP working Group} and Marika Pane and Concetta Palermo and Sonia Messina and Sansone, {Valeria A.} and Claudio Bruno and Michela Catteruccia and Maria Sframeli and Emilio Albamonte and Marina Pedemonte and Adele D'Amico and Giorgia Brigati and {de Sanctis}, Roberto and Giorgia Coratti and Simona Lucibello and Enrico Bertini and Giuseppe Vita and Tiziano, {Francesco Danilo} and Eugenio Mercuri",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.nmd.2018.05.010",
language = "English",
volume = "28",
pages = "582--585",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Nusinersen in type 1 SMA infants, children and young adults

T2 - Preliminary results on motor function

AU - on behalf of the Italian EAP working Group

AU - Pane, Marika

AU - Palermo, Concetta

AU - Messina, Sonia

AU - Sansone, Valeria A.

AU - Bruno, Claudio

AU - Catteruccia, Michela

AU - Sframeli, Maria

AU - Albamonte, Emilio

AU - Pedemonte, Marina

AU - D'Amico, Adele

AU - Brigati, Giorgia

AU - de Sanctis, Roberto

AU - Coratti, Giorgia

AU - Lucibello, Simona

AU - Bertini, Enrico

AU - Vita, Giuseppe

AU - Tiziano, Francesco Danilo

AU - Mercuri, Eugenio

PY - 2018/7/1

Y1 - 2018/7/1

N2 - We report preliminary data on the six month use of Nusinersen in 104 type 1 patients of age ranging from three months to 19 years, 9 months. Ten of the 104 were classified as 1.1, 58 as 1.5 and 36 as 1.9. Three patients had one SMN2 copy, 65 had two and 24 had three copies. In 12 the SMN2 copy number was not available. After six months an improvement of more than two points was found in 58 of the 104 (55.7%) on the CHOP INTEND and in 21 of the 104 (20.19%) on the Hammersmith Infant Neurological Examination (HINE). Changes more than two points were found in 26/71 patients older than two years, and in seven of the 20 older than 10 years. Changes ≥ four points were found in 20/71 older than two years, and in six of the 20 patients older than 10 years. The difference between baseline and six months on both CHOP INTEND and HINE was significant for the whole group (p < 0.001) as well as for the subgroups with two (p < 0.001), and three SMN2 copies (p < 0.001). Our preliminary results suggest that functional improvement can be observed in type 1 patients outside the range of the inclusion criteria used in the Endear study.

AB - We report preliminary data on the six month use of Nusinersen in 104 type 1 patients of age ranging from three months to 19 years, 9 months. Ten of the 104 were classified as 1.1, 58 as 1.5 and 36 as 1.9. Three patients had one SMN2 copy, 65 had two and 24 had three copies. In 12 the SMN2 copy number was not available. After six months an improvement of more than two points was found in 58 of the 104 (55.7%) on the CHOP INTEND and in 21 of the 104 (20.19%) on the Hammersmith Infant Neurological Examination (HINE). Changes more than two points were found in 26/71 patients older than two years, and in seven of the 20 older than 10 years. Changes ≥ four points were found in 20/71 older than two years, and in six of the 20 patients older than 10 years. The difference between baseline and six months on both CHOP INTEND and HINE was significant for the whole group (p < 0.001) as well as for the subgroups with two (p < 0.001), and three SMN2 copies (p < 0.001). Our preliminary results suggest that functional improvement can be observed in type 1 patients outside the range of the inclusion criteria used in the Endear study.

KW - CHOP INTEND

KW - Hammersmith Infant Neurological Examination

KW - Nusinersen

KW - Spinal Muscular Atrophy

KW - Werdnig Hoffmann disease

UR - http://www.scopus.com/inward/record.url?scp=85049004619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049004619&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2018.05.010

DO - 10.1016/j.nmd.2018.05.010

M3 - Article

AN - SCOPUS:85049004619

VL - 28

SP - 582

EP - 585

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 7

ER -